scholarly journals Amphetamine Use as a Risk Factor for Low-Dose Risperidone–Induced Acute Dystonia

2012 ◽  
Author(s):  
Isabelle Michaud ◽  
Pierre Landry
Keyword(s):  
Risk Factor ◽  
Low Dose ◽  
Acute Dystonia ◽  
Amphetamine Use

B-Vitamins, Methylenetetrahydrofolate Reductase (MTHFR) and Hypertension

2011 ◽  
Vol 81 (4) ◽  
pp. 240-244 ◽  
Author(s):  
Mary Ward ◽  
Carol P Wilson ◽  
J J Strain ◽  
Geraldine Horigan ◽  
John M. Scott ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Low Dose ◽  
Methylenetetrahydrofolate Reductase ◽  
Genetic Determinant ◽  
Gene Encoding ◽  
Homocysteine Concentration ◽  
Homozygous Mutant ◽  
B Vitamin

Hypertension is a leading risk factor for cardiovascular disease (CVD) and stroke. A common polymorphism in the gene encoding the enzyme methylenetetrahydrofolate reductase (MTHFR), previously identified as the main genetic determinant of elevated homocysteine concentration and also recognized as a risk factor for CVD, appears to be independently associated with hypertension. The B-vitamin riboflavin is required as a cofactor by MTHFR and recent evidence suggests it may have a role in modulating blood pressure, specifically in those with the homozygous mutant MTHFR 677 TT genotype. If studies confirm that this genetic predisposition to hypertension is correctable by low-dose riboflavin, the findings could have important implications for the management of hypertension given that the frequency of this polymorphism ranges from 3 to 32 % worldwide.

scholarly journals Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial

2019 ◽  
Vol 27 (3) ◽  
pp. 296-307 ◽  
Author(s):  
Thomas Vanassche ◽  
Peter Verhamme ◽  
Sonia S Anand ◽  
Olga Shestakovska ◽  
Keith AA Fox ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Peripheral Artery Disease ◽  
Low Dose ◽  
Cardiovascular Death ◽  
Peripheral Artery ◽  
Double Blind ◽  
Artery Disease ◽  
Risk Factor Status ◽  
Ischemic Events

Aims Secondary prevention in patients with coronary artery disease and peripheral artery disease involves antithrombotic therapy and optimal control of cardiovascular risk factors. In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) study, adding low-dose rivaroxaban on top of aspirin lowered cardiovascular events, but there is limited data about risk factor control in secondary prevention. We studied the association between risk factor status and outcomes, and the impact of risk factor status on the treatment effect of rivaroxaban, in a large contemporary population of patients with coronary artery disease or peripheral artery disease. Methods and results We reported ischemic events (cardiovascular death, stroke, or myocardial infarction) in participants from the randomized, double-blind COMPASS study by individual risk factor (blood pressure, smoking status, cholesterol level, presence of diabetes, body mass index, and level of physical activity), and by number of risk factors. We compared rates and hazard ratios of patients treated with rivaroxaban plus aspirin vs aspirin alone within each risk factor category and tested for interaction between risk factor status and antithrombotic regimen. Complete baseline risk factor status was available in 27,117 (99%) patients. Status and number of risk factors were both associated with increased risk of ischemic events. Rates of ischemic events (hazard ratio 2.2; 95% confidence interval 1.8–2.6) and cardiovascular death (hazard ratio 2.0; 1.5–2.7) were more than twofold higher in patients with 4–6 compared with 0–1 risk factors ( p < 0.0001 for both). Rivaroxaban reduced event rates independently of the number of risk factors ( p interaction 0.93), with the largest absolute benefit in patients with the highest number of risk factors. Conclusion More favorable risk factor status and low-dose rivaroxaban were independently associated with lower risk of cardiovascular events.

Is Chronic Exposure to Low-Dose Organochlorine Pesticides a New Risk Factor of T-cell Immunosenescence?

2018 ◽  
Vol 27 (10) ◽  
pp. 1159-1167 ◽  
Author(s):  
Dong-Hee Ryu ◽  
Hee Tae Yu ◽  
Se-A Kim ◽  
Yu-Mi Lee ◽  
Seon-Hui Hong ◽  
...  
Keyword(s):  
Risk Factor ◽  
T Cell ◽  
Organochlorine Pesticides ◽  
Chronic Exposure ◽  
Low Dose

scholarly journals New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy

2019 ◽  
Vol 44 (6) ◽  
pp. 1352-1362 ◽  
Author(s):  
Lina Shao ◽  
Juan Jin ◽  
Binxian Ye ◽  
Baihui Xu ◽  
Yiwen Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Risk Factor ◽  
Corticosteroid Therapy ◽  
Low Dose ◽  
Significant Difference ◽  
Dose Corticosteroid ◽  
New Onset Diabetes Mellitus ◽  
New Onset

Background: Idiopathic membranous nephropathy (IMN) is the most common cause of nephrotic syndrome in adults. Although various studies have demonstrated the efficacy of tacrolimus combined with corticosteroids for treating IMN, both tacrolimus and corticosteroids have been shown to be diabetogenic, particularly following organ transplantation. Furthermore, the frequency and risk factors for new-onset diabetes mellitus (NODM) in IMN patients treated with tacrolimus plus low-dose corticosteroids remain unclear. Objectives: To evaluate the incidence of NODM in IMN patients undergoing tacrolimus plus low-dose corticosteroid therapy and to confirm the risk factors for NODM development. Methods: This retrospective study recruited 72 eligible patients with biopsy-proven IMN from our center, between September 2013 and June 2018. All subjects were treated with tacrolimus plus low-dose corticosteroids for a minimum of 3 months. The primary outcome was NODM development during the follow-up period. The secondary outcome was complete or partial remission. Patients were divided into 2 groups: patients with NODM (NODM group) and those without NODM (No-NODM group). Demographic and clinical data at baseline and follow-up were assessed. Results: During follow-up, 31 of the 72 patients developed NODM (43.0%). The median time to occurrence was 3 months after treatment initiation. NODM patients were significantly older (median age 59 vs. 40 years) than No-NODM patients. Baseline fasting blood glucose levels were slightly higher in the NODM group; however, the difference was not significant (p = 0.07). Older age was an independent risk factor for NODM (OR 1.73 and 95% CI 1.20–2.47, p = 0.003). Overall kidney remission rates were 80.6%. There was no significant difference in remission rate between groups. There was a significant difference in development of pulmonary infection, which occurred in 7 NODM patients and only in 1 No-NODM patient (p = 0.018). IMN reoccurred in 5 NODM patients but only 1 No-NODM patient. Conclusions: Tacrolimus plus low-dose corticosteroid therapy was an efficient treatment for IMN; however, it was accompanied by increased NODM morbidity, which should be considered serious, due to the increased risk of life-threatening complications. Increasing age was a major risk factor for NODM in IMN patients treated with tacrolimus plus low-dose corticosteroid therapy.

scholarly journals Polycythaemia Rubra Vera: A Case Report & Review of Literature

1970 ◽  
Vol 6 (2) ◽  
pp. 114-116
Author(s):  
M Maksumul Haq ◽  
Sahela Nasrin ◽  
Syed Dawood Md Taimur ◽  
Hemanta I Gomes ◽  
Mohammad Arifur Rahman
Keyword(s):  
Risk Factor ◽  
Ischemic Stroke ◽  
Clinical Improvement ◽  
Low Dose ◽  
Review Of Literature ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Thrombotic Complications ◽  
Observation Period

We report a case of 73 year old woman with known risk factor (hypertension) for cerebrovascular disease who developed a TIA like symptom & vertigo with spontaneous clinical improvement. CT showed left cerebral infarct. Haematological test revealed PRV. Clinical improvement was associated with a reduction in haematocrit levels. Hydroxyurea appears to be the least leukemogenic myelosuppressive agent in long term prospective clinical PRV studies extending observation period of >10 years. Low dose aspirin will prevent the microvascular thrombotic complications of thrombocythaemia associated with PRV in remission after phlebotomy.Key words: Polycythaemia Rubra Vera(PRV); Thrombosis; Ischemic stroke DOI: 10.3329/uhj.v6i2.7259University Heart Journal Vol. 6, No. 2, July 2010 pp.114-116

scholarly journals Analyzing Correlation between Epicardial Fat Area and Metabolic Syndrome Risk Factor by Using Low-dose Lung CT

2015 ◽  
Vol 31 (5) ◽  
Author(s):  
HyonChol Jang ◽  
HaeKag Lee ◽  
Heon Lee ◽  
JangGyu Cha ◽  
YoonShin Kim ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Low Dose ◽  
Epicardial Fat ◽  
Metabolic Syndrome Risk Factor ◽  
Lung Ct
Sign in / Sign up

Export Citation Format

Share Document